Phoenicis Therapeutics CEO Deborah Ramsdell (L) and CMO Hal Landy
Six biotechs merge to take on BridgeBio, Abeona in 'butterfly skin' disease, with eyes also set on Duchenne
A relatively unknown clinical-stage biotech, with a medical chief who’s been involved in multiple BridgeBio ventures, has raised a small financing round and appears to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
